Imara - About the company
Imara is a public company based in Cambridge (United States), founded in 2016 by James McArthur. It operates as a Small molecules to treat rare blood diseases such as sickle cell disease. Imara has raised $94M in funding from investors like New Enterprise Associates, Orbimed and Bay City Capital. The company has 28 active competitors, including 5 funded and 12 that have exited. Its top competitors include companies like GBT, Emmaus Medical and LogicBio.
Company Details
Imara is developing novel therapeutics for patients suffering from sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and becomes damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Its lead candidate is IMR-687, a small molecule inhibitor of phosphodiesterase-9 (PDE9i) for the treatment of sickle cell disease.
- Website
- imaratx.com
- Social
- Email ID
- *****@imaratx.com
- Registered Address
- Cambridge (United States)
Key Metrics
Founded Year
2016
Location
Cambridge, United States
Stage
Public
Total Funding
$94M in 2 rounds
Latest Funding Round
Investors
Ranked
5th among 28 active competitors
Employee Count
41 as on Dec 31, 2021
Exit Details
Public
Legal entities associated with Imara
Imara is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
IMARA INC. CIN: 1672619 , United States, Active | - | - | - | |
Imara Inc CIN: 81-1523849 , United States, Active | Jan 25, 2016 | - | 41 (As on Dec 31, 2021) | - |
Imara's IPO details
Imara got listed on Mar 12, 2020.
Click here to take a look at Imara's IPO in detail
Sign up to download Imara's company profile
Imara's funding and investors
Imara has raised a total funding of $94M over 2 rounds. Its first funding round was on Apr 14, 2016. Its latest funding round was a Series B round on Mar 18, 2019 for $*****. 9 investors participated in its latest round. Imara has 9 institutional investors.
Here is the list of recent funding rounds of Imara:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 18, 2019 | 9331805 | Series B | 4855827 | 5068903 | 2703541 | 6052906 |
Apr 14, 2016 | 7354818 | Series A | 1221969 | 7877085 | 4291559 |
Access funding benchmarks and valuations. Sign up today!View details of Imara's funding rounds and investors
Imara's founders and board of directors
Founder? Claim ProfileThe founders of Imara is James McArthur. Rahul Ballal is the CEO of Imara.
Here are the details of Imara's key team members:
- James McArthur: Founder & President & CEO of Imara and founder of 1 other company. They are also an angel investor in 2 startups and serve on the board of 1 company.
- Rahul Ballal: CEO of Imara.
View details of Imara's Founder profiles and Board Members
Imara's employee count trend
Imara has 41 employees as of Dec 21. The total employee count is 52.0% more than what it was in Dec 20. Here is Imara's employee count trend over the years:
Uncover Imara's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Imara's Competitors and alternates
Top competitors of Imara include GBT, Emmaus Medical and LogicBio. Here is the list of Top 10 competitors of Imara, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | GBT 2011, San Francisco (United States), Acquired | Developer of small molecules for the treatment of sickle cell disease | $88.7M | 62/100 | |
2nd | Emmaus Medical 2000, Torrance (United States), Acquired | Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia | - | 61/100 | |
3rd |  LogicBio 2013, Lexington (United States), Acquired | Developer of viral vectors for the treatment of genetic and infectious diseases | $49M | 60/100 | |
4th | Developer of plasma-derived products for hemophilia and immune system deficiencies | $189M | 59/100 | ||
5th |  Imara 2016, Cambridge (United States), Public | Small molecules to treat rare blood diseases such as sickle cell disease | $94M | 57/100 | |
6th |  Cyclerion 2018, Cambridge (United States), Public | Developer of therapies for treating sickle cell disease and diabetic nephropathy | - | 55/100 | |
7th | _1591332761406.jpg?devicePixelRatio=2&height=30&width=30){kind=logo} Editas Medicine 2013, Cambridge (United States), Public | Developer of therapeutics for rare genetic diseases | $210M | 54/100 | |
8th | Octapharma 1983, Lachen (Switzerland), Unfunded | Developer of plasma derived therapeutics for multiple diseases | - | - | 54/100 |
9th | Sierra Oncology 2003, Vancouver (Canada), Acquired | Developer of targeted therapies to treat cancer | $75M | 54/100 | |
10th | Modus Therapeutics 2011, Stockholm (Sweden), Series B | Developers of polysaccharide based drug for the treatment of Sickle Cell Disease | $22.9M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Imara's competitors? Click here to see the top ones
Imara's Investments and acquisitions
Imara has made no investments or acquisitions yet.
News related to Imara
Filter this list•
Basata boosts Your Payments stake with Jordanian banks and the Social Security Fund.Alalamelyoum•Feb 24, 2025•Anniston, Imara, Al Tamimi, Arab Bank and 2 others
•
•
Rahul D. Ballal Sells 3,237 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockfinnewslive.com•Apr 04, 2024•Imara
•
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares of Stockreporter.am•Feb 21, 2024•Imara
•
Imara Announces Stockholder Approval of Merger With EnlivenGlobeNewswire•Feb 23, 2023•Enliven Therapeutics, Imara
•
G.O.A.T Brand Labs expands its purse of ethnic lifestyle brandsAdgully•Jan 25, 2023•GOAT Brand Labs, Imara
•
Weiss Law Reminds Sal, Shbi, Hznp, And Imra Shareholders About Its Ongoing InvestigationsPR Newswire•Jan 20, 2023•, Salisbury Bank, Shore United Bank, Horizon Therapeutics and 1 other
•
Contact the M&A Class Action Firm Regarding Its Investigation of the Merger – LBAI, LMST, SRYB, IMRAGlobeNewswire•Jan 19, 2023•Monteverde, Lakeland Bank, Limestone Bank, Surrey Bank and 1 other
•
Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRAPR Newswire•Jan 12, 2023•Kahn Swick & Foti, Imara
•
Contact the M&A Class Action Firm Regarding Its Investigation of the Merger – APEN, SRYB, LMST, IMRAGlobeNewswire•Jan 12, 2023•Monteverde, Apollo Endo, Surrey Bank, Limestone Bank and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Imara
Explore our recently published companies
- Ford Country - Henderson based, 1996 founded, Unfunded company
- A2Z Creations - Panipat based, 2015 founded, Unfunded company
- IRG Commercial - Altamonte Springs based, 1989 founded, Unfunded company
- GMR Quality Stone Products - Sterling Heights based, 2002 founded, Unfunded company
- Socalweb - Los Angeles based, 2004 founded, Unfunded company
- The Darnell Works Agency - Asheville based, 2000 founded, Unfunded company
